HCW Biologics shares rose 8.20% to $1.32 following a Q1 2026 report showing a swing to a $3.47 million net income. The surge is primarily attributed to a $6.5 million licensing deal with Beijing Trimmune Biotech.
- The company continues to face going concern risks with cash reserves totaling only $1.23 million.
- Future catalysts include upcoming clinical data readouts for the alopecia treatment HCW9302 and an active appeal against a Nasdaq delisting.